11,150 Shares in GSK plc (NYSE:GSK) Bought by Michels Family Financial LLC

Michels Family Financial LLC purchased a new position in GSK plc (NYSE:GSK - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,150 shares of the pharmaceutical company's stock, valued at approximately $377,000.

A number of other hedge funds also recently made changes to their positions in GSK. Dorsey & Whitney Trust CO LLC boosted its position in GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares in the last quarter. Northwest Bank & Trust Co raised its position in shares of GSK by 1.3% in the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after acquiring an additional 289 shares in the last quarter. GC Wealth Management RIA LLC grew its position in shares of GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after buying an additional 353 shares during the period. Jacobi Capital Management LLC increased its stake in GSK by 3.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC boosted its holdings in GSK by 3.4% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock worth $413,000 after acquiring an additional 407 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

Shares of NYSE GSK traded up $0.78 during trading hours on Tuesday, reaching $39.44. 3,511,831 shares of the stock traded hands, compared to its average volume of 4,830,909. The company has a market capitalization of $81.37 billion, a P/E ratio of 24.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.01. The company's 50-day simple moving average is $37.26 and its two-hundred day simple moving average is $36.04.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The company had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter last year, the company earned $0.43 EPS. The firm's revenue was up 2.1% compared to the same quarter last year. Equities research analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.28%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 86.60%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several analyst reports. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.